Drug Profile
Lorazepam intranasal - Intranasal Therapeutics
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Ikano Therapeutics
- Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anxiety disorders; Seizures; Sleep disorders
Most Recent Events
- 22 May 2009 Discontinued - Phase-I for Anxiety disorders in USA (Intranasal)
- 22 May 2009 Discontinued - Phase-I for Seizures in USA (Intranasal)
- 08 Mar 2007 Intranasal lorazepam is still in phase I trials for anxiety disorders and seizures in the US